Merck & Co. Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Merck & Co. Bundle
What is included in the product
Detailed Word Document
Merck's BCG Matrix breakdown: investment, hold, or divest strategies.
Customizable Excel Spreadsheet
Export-ready design for quick drag-and-drop into PowerPoint to streamline executive presentations.
Full Transparency, Always
Merck & Co. BCG Matrix
The BCG Matrix previewed here is the complete document you'll receive after purchase, representing Merck & Co.'s strategic portfolio. This fully formatted, ready-to-use report provides an in-depth analysis of Merck's business units. Download the analysis directly; no alterations needed, the same file is yours.
BCG Matrix Template
See the Bigger Picture
Merck & Co.'s product portfolio reveals diverse market positions. This BCG Matrix analysis classifies key products across Stars, Cash Cows, Dogs, and Question Marks. Understand which offerings drive growth and which require strategic attention. This snapshot provides a glimpse into Merck's competitive landscape. Get the complete BCG Matrix for detailed quadrant placements and strategic recommendations, including actionable insights you can use today.
Stars
Keytruda
Keytruda, Merck's leading PD-1 inhibitor, leads the oncology market. It's a cash cow, generating significant revenue. In 2023, Keytruda brought in approximately $25 billion. Merck is broadening Keytruda's applications.
Animal Health Business
Merck's Animal Health division is a Star in its BCG Matrix, consistently delivering strong revenue contributions. In 2024, the division's growth was fueled by pricing and demand for livestock and companion animal products. The Elanco aqua acquisition further solidified its market position. This division is a key growth driver for Merck, with a 2024 revenue of $6.5 billion.
WINREVAIR
WINREVAIR, a recent addition to Merck & Co.'s portfolio, shines as a Star in the BCG matrix. Approved in March 2024, it's rapidly boosting sales. The drug is eyed for expansion in markets like China. Positive Phase 3 trial data solidifies its growth potential.
Subcutaneous Pembrolizumab
The subcutaneous pembrolizumab, an investigational formulation of Merck's Keytruda, is a star in the BCG matrix. Positive results from a Phase 3 trial have led to FDA filing acceptance, with a PDUFA date in September 2025. This could significantly reduce administration time for patients. Keytruda's 2024 sales reached approximately $25 billion, making it a blockbuster drug.
- FDA filing acceptance for subcutaneous pembrolizumab.
- PDUFA date set for September 2025.
- Keytruda's 2024 sales: ~$25 billion.
- Potential for improved patient convenience.
Capvaxive
Capvaxive, Merck's new pneumococcal vaccine, is a Star in the BCG Matrix due to its recent approval. The European Commission approved Capvaxive, marking a significant market entry. This vaccine could challenge Pfizer's Prevnar, positioning it for rapid market share growth. The vaccine market is substantial, with pneumonia vaccines generating billions annually.
- Approval by the European Commission is a key milestone.
- Capvaxive targets a large market, including invasive pneumococcal disease and pneumonia.
- This launch is expected to contribute to Merck's revenue growth.
- The vaccine market is valued in the billions of dollars annually.
Stars Shine Bright in the Portfolio!
In Merck's BCG matrix, multiple products are categorized as Stars due to their high market growth and share. Keytruda, a leading oncology drug, is a Star, generating approximately $25 billion in 2024 sales. The Animal Health division, contributing $6.5 billion in 2024, is also a key Star. Other stars include WINREVAIR and Capvaxive.
| Star Product | Description | 2024 Sales/Contribution |
|---|---|---|
| Keytruda | PD-1 inhibitor | ~$25 billion |
| Animal Health | Livestock & Companion Animal Products | $6.5 billion |
| WINREVAIR | Recently approved drug | Rapidly boosting sales |
Cash Cows
Gardasil/Gardasil 9 (excluding China)
Gardasil/Gardasil 9, Merck's HPV vaccine, is a cash cow. In 2024, sales outside China showed strong demand. The vaccine's market presence and use in HPV prevention are key. For Q1 2024, Gardasil/Gardasil 9 global sales were $1.9 billion.
Pharmaceuticals
Merck's pharmaceutical division remains a cash cow, fueled by innovative medicines and established brands. In 2024, this segment saw a rise in net sales, boosted by robust sales and cost control. Merck is strategically focusing its portfolio on future growth, anticipating continued profitable growth in 2025 after a strong Q4 2024. For instance, Keytruda, a key product, generated around $6.8 billion in sales during the first nine months of 2024.
BRAVECTO
BRAVECTO, a key product in Merck's animal health division, is a cash cow. It generates steady revenue due to strong market demand. In 2024, the animal health sector saw continued growth, benefiting products like BRAVECTO. This product's consistent sales support Merck's financial stability.
Vaccines (excluding HPV)
Merck's vaccine portfolio, excluding HPV, is a cash cow, consistently generating substantial revenue. It's a key player in the pediatric vaccine market, with a significant market share. Demand for vaccines remains strong, securing its cash cow status. The company's efforts to update its portfolio ensures continued revenue.
- In 2023, Merck's vaccine sales (excluding HPV) reached approximately $8.5 billion.
- Merck holds a leading position in the U.S. pediatric vaccine market.
- Ongoing vaccine updates and new product launches contribute to its sustained revenue.
- Demand for vaccines is relatively stable, providing predictable cash flow.
Established Franchises
Merck's established franchises, such as Keytruda, are cash cows, ensuring financial stability. These franchises hold strong market positions, enjoying consistent revenue. They generate significant cash flow, supporting R&D and strategic investments. Keytruda's 2023 sales were $25 billion, highlighting its cash-generating power.
- Keytruda's sales in 2023: $25 billion.
- These franchises have well-established market positions.
- They provide consistent revenue streams.
- Cash flow supports R&D and investments.
Top Performers Fueling Financial Strength
Merck's cash cows are major revenue drivers, offering financial stability and supporting growth. Keytruda and Gardasil/Gardasil 9 are top performers, with Keytruda's 2023 sales hitting $25 billion. These products hold strong market positions, ensuring consistent cash flow for Merck.
| Cash Cow | 2023 Sales | Market Position |
|---|---|---|
| Keytruda | $25B | Leading |
| Gardasil/Gardasil 9 | Significant | Strong |
| BRAVECTO | Steady | Growing |
Dogs
LAGEVRIO
LAGEVRIO, Merck's COVID-19 treatment, faces declining sales due to reduced pandemic demand. As of Q3 2023, LAGEVRIO sales were $153 million, significantly down from previous quarters. This decline positions LAGEVRIO as a potential "dog" in Merck's BCG matrix, with limited growth prospects.
SIMPONI and REMICADE
Merck's SIMPONI and REMICADE faced a shift in October 2024. Marketing rights moved back to Johnson & Johnson. This change has impacted sales negatively. As a result, these products might be classified as dogs. This is due to their reduced revenue contribution for Merck.
Surface Solutions
Surface Solutions, part of Merck's Electronics, saw sales declines, with €406 million in sales. This indicates a potential "Dog" status in the BCG Matrix. Dogs typically have low market share and growth. This suggests Surface Solutions may be underperforming revenue-wise within Merck's portfolio.
Display Solutions (Optronics)
Display Solutions, rebranded as Optronics in January 2025, saw sales of €748 million. This unit, within the Electronics sector, experienced a sales downturn in 2024. Based on these figures, Optronics likely falls into the "Dogs" category within Merck's BCG matrix. This suggests a low market share in a slow-growth industry, potentially warranting divestiture or restructuring.
- 2024 Sales Decline: Optronics faced declining sales.
- Low Revenue Contribution: The unit’s impact on overall revenue is limited.
- BCG Matrix: Likely categorized as "Dogs" in Merck's portfolio.
- Strategic Implications: Potential for divestiture or restructuring.
Life Science Services
In 2024, Merck's Life Science Services saw sales drop to €722 million, signaling a potential shift in its BCG Matrix classification. This decline suggests the unit may now be considered a "dog" within Merck's portfolio, as it doesn't significantly boost revenue. Dogs typically have low market share and growth, requiring careful management to avoid draining resources.
- 2024 Sales: €722 million.
- BCG Status: Potential "Dog" classification.
- Implication: Low market share and growth.
Underperforming Units: A Strategic Shift?
Several Merck units are potentially "dogs" in the BCG matrix, with low market share and growth. LAGEVRIO's 2023 sales were significantly down to $153M. SIMPONI/REMICADE sales were negatively impacted by the 2024 rights shift.
Surface Solutions saw €406M in sales, and Optronics, rebranded in January 2025, reported €748M in 2024, both indicating downturns. Life Science Services' 2024 sales fell to €722M.
These units might be candidates for divestiture or restructuring. The "dog" classification typically reflects low revenue contribution and limited prospects for growth. The strategic focus is to manage or eliminate these underperforming assets.
| Unit | Sales Metric (2024) | BCG Status Implication |
|---|---|---|
| LAGEVRIO | Declining Sales (2023: $153M) | Potential "Dog" |
| SIMPONI/REMICADE | Sales Impacted (2024) | Potential "Dog" |
| Surface Solutions | €406M | Likely "Dog" |
| Optronics | €748M (2024) | Likely "Dog" |
| Life Science Services | €722M (2024) | Potential "Dog" |
Question Marks
Lynparza
Lynparza, a key oncology drug, brought in $1.311 billion in revenue. This positions Lynparza as a question mark within Merck & Co.'s BCG Matrix. There's significant growth potential for Lynparza, especially with expanded indications. If sales continue to climb, it could evolve into a star product for Merck.
WELIREG
WELIREG, a novel HIF-2α inhibitor, is part of Merck's oncology portfolio. It has demonstrated promising sales growth. WELIREG has received approval in China. Further expansion into new markets and indications could position WELIREG as a star. In 2024, Merck's oncology sales are projected to be significant.
Oral PCSK9 Inhibitor
Merck's oral PCSK9 inhibitor is a question mark in its BCG matrix, signaling high potential but uncertain outcomes. Phase 3 results are expected in 2024, influencing its market position. Success could transform it into a blockbuster, significantly impacting Merck's revenue. Cardiovascular diseases represent a $300+ billion market globally.
Infectious Disease and Vaccines Pipeline
Merck's infectious disease and vaccines pipeline is a promising area for future growth. These programs aim to meet unmet medical needs, potentially leading to substantial revenue. Their success depends on successful development and commercialization efforts. The pipeline includes vaccines and treatments for various infectious diseases.
- In 2023, Merck's vaccine sales reached $9.7 billion.
- Key vaccine candidates target diseases like RSV and pneumococcal disease.
- Successful launches could significantly boost Merck's revenue.
Cardiometabolic Pipeline
Merck's cardiometabolic pipeline, including oral PCSK9 inhibitors and dual agonists, could be a future growth area. These assets, with anticipated approvals by 2030, could potentially become stars. These are expected to generate significant revenue. This aligns with Merck's strategic focus on expanding its portfolio.
- Oral PCSK9 inhibitors and dual agonists are part of the cardiometabolic pipeline.
- Approvals are anticipated by 2030, indicating a long-term investment.
- These assets hold the potential to generate substantial revenue.
- This could lead to a significant shift in Merck's portfolio.
Question Marks: The Path to Growth
Merck's question marks include Lynparza, with $1.311B in revenue, and an oral PCSK9 inhibitor. WELIREG also fits the category, showing promising sales growth. These products require strategic investment and market execution to become stars.
| Drug | Revenue (2023) | Status |
|---|---|---|
| Lynparza | $1.311B | Question Mark |
| WELIREG | Growing | Question Mark |
| PCSK9 Inhibitor | Pending Phase 3 | Question Mark |
BCG Matrix Data Sources
Merck's BCG Matrix utilizes comprehensive data: financial filings, market research, and sales figures.
